AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01201551 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Brimonidine
Description: Week1, day2: 1 eyedrop/right eye Week2, day1: 1 eyedrop/left eye Week2, day2: 1 eyedrop/left eye
Study NCT01201551 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Latanoprost
Description: Week1, day1: 1 eyedrop/right eye Week1, day2: 1 eyedrop/right eye Week2, day2: 1 eyedrop/left eye
Study NCT01201551 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Week1, day1: 1 eyedrop/left eye Week1, day2: 2 eyedrops/left eye Week2, day1: 1 eyedrop/right eye Week2, day2: 2 eyedrops/right eye
Study NCT00112866 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cilengitide
Description: Given IV
Study NCT00112866 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: therapeutic conventional surgery
Description: Undergo tumor resection
Study NCT03963713 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic radiotherapy
Description: Using multimodal image fusion to outline the target area.PTV = GTV + 0-10mm Target volume radiation dose: The range of BED value of radiotherapy was 60-72 when the distance between the tumor and gastrointestinal tract or spinal cord was more than 5 mm (alpha/beta=10) and 51.3-59.5 when the distance between the tumor and gastrointestinal tract or spinal cord was less than 5 mm (alpha/beta=10).
Study NCT00112866 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Correlative studies
Study NCT00112866 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT02070497 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: case management
Description: case management group will accept the case manager's service; the control group will just accept the routine care
Study NCT03963713 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Conventionally-fractionated image- guided Intensity modulated radiotherapy
Description: Using multimodal image fusion to outline the target area.The dose of the target volume radiotherapy dose is 30 Gy/10f or 40Gy/20f.Previous treatment and follow-up data will be analyzed to evaluate the clinical efficacy comparison of stereotactic radiotherapy and conventionally-fractionated image-guided intensity-modulated radiotherapy for spinal metastatic tumors, local control rate and side effects, and to clarify the effectiveness and safety of different doses of radiotherapy.
Study NCT00917319 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Bundling Infection Control Interventions
Description: identify risk factors for developing HAIs, receive general infection control measures as well as infection control measures appropriate for the identified risk factor (s)
Study NCT02422082 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: L. reuteri
Description: Dietary supplementation with L. reuteri twice daily for 12 months
Study NCT02422082 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Dietary supplementation with placebo twice daily for 12 months
Study NCT04157699 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TDF tablet
Description: TDF tablet 300mg QD
Study NCT02833701 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Ascorbic Acid
Description: Given IV
Study NCT04404361 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pacritinib
Description: 100 mg capsules
Study NCT02833701 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Given intravenously (IV)
Study NCT02833701 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT02833701 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT04404361 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo capsules matching pacritinib 100 mg capsules
Study NCT04232995 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Balance Training
Description: Balance enhancing exercises
Study NCT04477915 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Core exercises
Description: Core stabilization exercise include, plank, lateral plank, swimmer, flutter kick and bridge exercises.
Study NCT04157699 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TDF tablet
Description: TDF tablet 300mg QD
Study NCT04157699 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: QL-007
Description: QL-007 tablet
Study NCT02540590 — intervention group
Intervention type: DEVICE
Intervention: laser speckle contrast imaging of the oral mucosa
Description: Non-invasive method to measure tissue blood perfusion applied for oral mucosa
Study NCT02540590 — intervention group
Intervention type: DEVICE
Intervention: wound fluid measurement
Description: Wound fluid at the gingival sulcus was volumetrically measured by Periotron 8000 instrument using filter strip
Study NCT02473783 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sertraline HCl
Description: The regimen of Sertraline HCl will be administered with starting dose from minimum 25 mg/day for 1 week and maintenance dose of at least 50 mg/day up to 200 mg/day for the rest of 5 weeks.
Study NCT02011269 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Trichuris Suis Ova
Study NCT02011269 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Trichuris Suis Ova
Study NCT01428219 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabozantinib
Description: Cabozantinib is available in capsule form. The dose is 60 mg daily by mouth. Subjects with disease progression at 6 weeks who do not have significant toxicities may remain on therapy for an additional six weeks until a progression is confirmed. Further study drug administration beyond 12 weeks will be at the discretion of the investigator provided that the subject does not have disease progression, does not have unacceptable side effects, does not withdraw from study, or does not have a medical condition or illness that renders the subject unacceptable to receive further study drug.
Study NCT00533130 — intervention group
Intervention type: PROCEDURE
Intervention: clinical evaluation
Description: analyze the x ray from each patient and evaluate the treatment y development of bone healing.
Study NCT00533130 — intervention group
Intervention type: PROCEDURE
Intervention: observational study
Description: evaluate the walk patron, bone healing and range of motion at 1,3,6,12 months
Study NCT00783432 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Astepro Nasal Spray (0.1% azelastine hydrochloride)
Description: 548 mcg (2 sprays per nostril) twice a day
Study NCT00783432 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Astelin Nasal Spray (0.1% azelastine hydrochloride)
Description: 548 mcg (2 sprays per nostril) twice a day
Study NCT01615744 — intervention group
Intervention type: PROCEDURE
Intervention: Open Reduction Internal Fixation
Description: Lateral approach through extensile lateral incision ( Benirschke), Reduction ( Soeur et Remy) and internal fixation with lateral plating with or without bone graft
Study NCT01615744 — intervention group
Intervention type: PROCEDURE
Intervention: Non-surgical management
Description: Early active exercises and elevation to decrease swelling
Study NCT02102958 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: DSME with Nonvisual Foot Examination
Description: Diabetes Self-Management Education (DSME) with Nonvisual Foot Examination included comprehensive DSME taught by Certified Diabetes Educators that included instruction in nonvisual self-examination of feet using the senses of touch and smell.
Study NCT02102958 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: DSME with Usual Foot Examination Instruction
Description: DSME with usual foot examination instruction was comprehensive diabetes self management education taught by Certified Diabetes Educators that included usual care instructions for examination for feet at home by visually impaired persons, i.e., to have a sighted person check the feet regularly.
Study NCT04884503 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clonazepam tablets
Description: Dosing of clonazepam was as follows: in the first week, 1 mg to be sucked for 2 minutes, then swallowed (once a day in the morning), in the second week, 1 mg to be sucked for 2 minutes, and then swallowed (twice a day in the morning and one hour before falling asleep), in the third week, 1 mg to be sucked for 2 minutes and in the fourth week 1 mg to be sucked for 2 minutes, then swallowed (once a day in the morning)
Study NCT04884503 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: tongue pads
Description: wearing a tongue pad 3 times a day for 20 minutes for 4 weeks
Study NCT02471053 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Moderate Intensity Exercise
Description: Exercise sessions will be held twice-weekly and will begin with a group warm-up activity, followed by 45 minutes of aerobic activity and ending with a cool down. All aerobic exercise will be performed at a moderate intensity, defined as exercise that elicits a heart rate (HR) between 40-60% of heart rate reserve (HRR). Prior to the initial exercise session target heart rates will be calculated for each subject based on the maximum HR achieved during their baseline stress test.
Study NCT02473783 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: I-123-ADAM SPECT
Description: The subjects underwent the SPECT scan after I-123-ADAM (185 MBq, 5mCi) IV injection.
Study NCT03868462 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Optos P200TE
Description: The P200TE Ophthalmoscope provides widefield Scanning Laser Ophthalmoscope (SLO) fundus imaging and Optical Coherence Tomography (OCT) imaging in one device.
Study NCT03868462 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Predicate Device
Description: The predicate device is an optical coherence tomography system intended for in vivo imaging, axial cross-sectional, three-dimensional imaging and measurement of anterior and posterior ocular structures.
Study NCT03918109 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OTO-313
Description: single intratympanic injection of gacyclidine
Study NCT03918109 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: single intratympanic injection of placebo
Study NCT03002662 — intervention group
Intervention type: OTHER
Intervention: colonoscopy
Study NCT03163004 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Implementation of standing desks
Description: Three standing desks will be introduced to the classroom
Study NCT03952611 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Colonoscopy
Description: Using an instrument called colonoscope which is used to detect colonic polyps
Study NCT03952611 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: distal Cap
Description: Using an instrument called cap at end of colonoscope which is used to straighten colon folds
Study NCT03952611 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Endocuff
Description: Using an instrument called Endocuff at end of colonoscope which is used to straighten colon folds
Study NCT02870387 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Comprehensive Care with Inpatient consultation
Description: Comprehensive care with Inpatient Consultation: HRCC patients randomized to the comprehensive care with inpatient consultation group that are admitted to CMHH will receive inpatient consultation by HRCC providers during their stay with input and recommendations conveyed to the hospital inpatient team on admission and at discharge at a minimum (in person consultations on weekdays and phone consultations on the weekends). The HRCC providers will review the inpatient care plan and will make treatment and discharge recommendations with a focus on coordination and integration of inpatient and outpatient care. Ideally, the inpatient consultations are face-to-face meetings with the hospital inpatient team but could also be a phone call or a consult note written in the medical record.
Study NCT02870387 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual Inpatient Care
Description: High-Risk Children's Clinic (HRCC) patients randomized to the usual inpatient care group who are admitted to Children's Memorial Hermann Hospital (CMHH) will receive usual inpatient care from the primary hospital admitting team (residents and fellows supervised by pediatric faculty physicians) with usual occasional communication with the patient's assigned HRCC provider. HRCC patients admitted to CMHH in this treatment group will receive usual inpatient care that is not modified by the study protocol.
Study NCT04477915 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Auxiliary respiratory exercises
Description: Auxiliary respiratory exercises include, strengthening and stretching exercises for trapezius, sternocleidomastoideus, pectoralis major and serratus anterior muscles.
Study NCT02978209 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: 7.5 %
Description: Patient untreated with moisturizers for 1-2 weeks will start applying moisturizers containing urea at concentration 0 % on one half of the body twice a day while applying the same moisturizer with 7.5 % urea on the other half of the body in the same quantity at the same frequence
Study NCT02392494 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-1075
Description: MK-1075 supplied as 10 mg or 100 mg tablets for oral administration.
Study NCT02491281 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LNA043
Description: ascending single dose on Day 1; 1 to 4 week(s) prior total knee replacement surgery
Study NCT02491281 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: ascending single dose on Day 1; 1 to 4 week(s) prior total knee replacement surgery
Study NCT00143559 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Systematic chemotherapy and antibodies
Description: Systemic chemotherapy and antibodies as follows:~Transplant recipients received a reduced intensity conditioning regimen consisting of OKT-3, fludarabine, thiotepa, and melphalan followed by an infusion of a T-cell depleted haploidentical hematopoietic stem cell graft. The antibody Rituximab was administered within 24 hours of the infusion in an effort to prevent PTLPD. In addition to T -cell depletion of the donor product, Mycophenylate mofetil was provided over several months as prophylaxis for GVHD
Study NCT00143559 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Allogeneic stem cell transplantation
Description: An infusion of HLA mismatched family member donor stem cells processed through the use of the investigational Miltenyi Biotec CliniMACS device
Study NCT00143559 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Miltenyi CliniMACS
Description: Miltenyi Biotec CliniMACS stem cell selection device
Study NCT02518100 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vital Signs Patch (VSP) System 3-Lead (NEHB) Configuration
Description: Vital signs will be taken using the Vital Signs Patch (VSP) System 3-Lead (NEHB) Configuration on each study participant in each Arm of this study for comparison against the same vital signs taken with traditional methods used by the facility.
Study NCT02518100 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vital Signs Patch (VSP) System 1-Lead (PAL) Configuration
Description: Vital signs will be taken using the Vital Signs Patch (VSP) System 1-Lead (PAL) Configuration on each study participant in each Arm of this study for comparison against the same vital signs taken with traditional methods used by the facility.
Study NCT00436319 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Duration of GnRH agonist downregulation
Description: This is a randomized controlled trial. Patients will be randomized to two groups during the first consultation. GnRH agonist will be administrated according to the long luteal protocol. Down-regulation of the pituitary will be controlled on the first day of the menstrual period.~The purpose of this study is to compare the pregnancy rates between the two groups. In the eventuality that pituitary down-regulation has not been confirmed (down-regulation levels determined as Ε2\<80 pg/ml and progesterone \<1.6 ng/ml), the patient will be assigned to a third group (group 3) and ovarian stimulation will only be initiated after down-regulation has been confirmed.~The GnRH agonist that will be administrated is Buserelin Acetate. Recombinant FSH will be used for the ovarian stimulation and dose determination will be based on patient characteristics and previous history.
Study NCT01684891 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RG1662
Description: multiple doses of RG1662
Study NCT03489681 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: acupuncture
Description: Low dose group:~Twenty patients will assign for low dose group treatment; as six acupoints as Shensu (BL 54), Huantiao (GB 30), Weizhong (BL 40), Yanglingquan (GB 34), Kunlun (BL 60), Juegu (GB 39).~High dose group:~Twenty patients will assign for high dose group treatment. These acupoints contains of eighteen acupoints, as Shenshu (BL 54), Dachangshu (BL 25) , Xiaochangshu (BL 27), Huantiao (GB 30), Yinmen (BL 37) , Zhibien (BL 54), Chengfu (BL 36), Fengshi (GB 31), Weizhong (BL 40), Zusanli (ST 36) Yanglingquan (GB 34), Yinlingquan (SP 9), Feiyang (BL 58), Sanyinjiao (SP 6), Juegu (GB 39), KunLun (BL 60), , Taixi (KI 3), Shenmai (BL 62).
Study NCT00425477 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: sargramostim
Study NCT00425477 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bexarotene
Study NCT00425477 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: cytogenetic analysis
Study NCT00425477 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: fluorescence in situ hybridization
Study NCT00425477 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: flow cytometry
Study NCT00425477 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Study NCT00425477 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: biopsy
Study NCT01005446 — intervention group
Intervention type: DEVICE
Intervention: Encore Reverse Shoulder Prosthesis (RSP®)
Description: The RSP is indicated for use in subjects with grossly rotator cuff deficient shoulder joints with severe arthropathy or a previously failed joint replacement with a grossly rotator cuff deficient shoulder joint.
Study NCT00476996 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leflunomide
Description: Oral repeating dose
Study NCT00450619 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Samarium Sm 153 lexidronam pentasodium
Description: 1 mCi/Kg given intravenous (IV)over 1 minute on day 8.
Study NCT00450619 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Sargramostim
Description: 100 mcg/injection x 4 days given subcutaneously
Study NCT00476996 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Leflunomide
Description: Oral repeating dose
Study NCT00476996 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Oral or parenteral repeating dose
Study NCT00476996 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Methotrexate
Description: Oral or parenteral repeating dose
Study NCT00476996 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ocrelizumab
Description: Intravenous repeating dose (200mg)
Study NCT04232995 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: General Exercises
Description: General Exercises
Study NCT04232995 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: General Exercises
Description: General Exercises
Study NCT00476996 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ocrelizumab
Description: Intravenous repeating dose (500mg)
Study NCT00476996 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Intravenous repeating dose
Study NCT03121118 — intervention group
Intervention type: OTHER
Intervention: Scan Opportunity
Description: Participants in the scan group are provided the option of having an amyloid PET brain scan and receiving their results which can inform them of risk for developing Alzheimer's Disease.
Study NCT01504048 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Colonoscopy with Indigo-Carmine Chromoendoscopy
Description: Colonoscopy with chromoendoscopy using 0.2-0.5% Indigo-Carmine solution sprayed in five areas of the large intestine: Cecum, ascending colon, transverse colon, descending colon and rectum. Pictures are taken before and after dye-spraying and biopsies are collected from all segments of the large intestine and rectum.
Study NCT03874754 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tailored Technology-Enhance Home-based exercise program (iHBE)
Description: The tailored technology enhanced home-based exercise (iHBE) program is a 12-week program with 1 assessment home visit session, 5 home visits and 7 phone follow ups during exercise. The technologies, a wearable device, and a smartphone application, will be used as a tool to monitor physical performance (heart rate \[HR\], step count), provide immediate feedback, send daily reminding message through Mobile Ecological Momentary Assessment (mEMA). The coded raw data without personal identification information from the wearable device will be sent to the servers where the investigators can store it in the database alongside the mEMA data and create custom reports showing Heart Rate (HR) 30 minute before each Ecological Momentary Assessment (EMA) survey, showing HR and previous self-report responses before/ after each automatically triggered EMA.